Mothaffar F. Rimawi

Mothaffar F. Rimawi, M.D. is the Dan L Duncan Professor and Executive Medical Director & Associate Director of Clinical Affairs at the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. His work bridges laboratory research and clinical practice, focusing on HER2-positive, ER-positive, and triple-negative breast cancer. He leads clinical trials for novel therapies, including neoadjuvant treatment optimization and targeted therapy development.

• Education: MD from University of Jordan; Residency & Fellowships at Baylor College of Medicine

His research explores biomarker-driven treatment strategies, mechanisms of drug resistance, and proteogenomic profiling to improve outcomes in advanced breast cancer. Recent articles highlight IRE1alpha's role in triple-negative breast cancer and proteostasis network modulation in KRAS inhibitor resistance.

Scientific contributions include pivotal clinical trials like KATHERINE (Trastuzumab Emtansine in residual HER2+ disease) and ATEMPT (adjuvant therapy for stage I HER2+ cancer). He is board-certified in Internal Medicine, Medical Oncology, and Hematology, with affiliations to organizations including ASCO and ASH.